Pharmaceutical Research
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Clinical Trial
Tonix Pharmaceuticals has received FDA clearance to begin Phase 2 trials for TNX-2900, a potential treatment for Prader-Willi syndrome, marking significant progress for a rare genetic disorder that causes life-threatening childhood obesity.
Cybin Receives Australian Approval for Phase 3 Study of Psychedelic-Based Depression Treatment
Cybin Inc. has secured Australian regulatory approval to conduct its EMBRACE Phase 3 clinical trial of CYB003, a novel deuterated psilocin analog, marking a significant advancement in developing next-generation treatments for major depressive disorder.
Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
Creative Biolabs has expanded its liposomal drug delivery services to support advancements in gene therapy, oncology, and molecular medicine, offering customized solutions for research institutions and pharmaceutical industries worldwide.
Cybin Inc. Advances Mental Health Treatments with Q1 2025 Results and Key Program Updates
Cybin Inc. reports significant progress in its Phase 3 depression program and Phase 2 anxiety study, highlighting advancements in next-generation mental health treatments.
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns
Soligenix Inc. is progressing with RiVax®, a heat-stable vaccine against ricin toxin, showcasing significant potential in biodefense and public safety.
Oragenics Inc. Advances Toward Phase IIa Concussion Trial with ONP-002
Oragenics Inc. (NYSE American: OGEN) is making significant progress with its lead candidate, ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion, highlighting the potential of its intranasal delivery technology in transforming neurological care.
Amerigo Scientific Enhances Research Accuracy with Premium Carotenoid Standards
Amerigo Scientific's introduction of high-purity carotenoid standards marks a significant advancement in ensuring reliable and reproducible analytical results for industries reliant on precise carotenoid quantification.
Creative Biolabs Enhances Antibacterial Drug Development with Integrated Mechanism and Pharmacokinetic Strategies
Creative Biolabs is revolutionizing antibacterial drug development by integrating mechanism identification and pharmacokinetic modeling early in the process to mitigate risks and enhance success rates.
Quantum BioPharma Ltd. Advances in Brain and Alcohol Health Research with Phase 2 Trial Approval
Quantum BioPharma Ltd. makes significant strides in its brain disorders and alcohol health pipeline, including Phase 2 trial approval for FSD202 and preparations for an IND filing for Lucid-MS, highlighting its commitment to addressing unmet medical needs.
Cybin Inc. Advances Phase 3 Psychedelic Therapeutics Program, Signaling Progress in Mental Health Treatment
Cybin Inc. reports significant progress in its Phase 3 clinical trials for CYB003, a novel treatment for major depressive disorder, highlighting the potential of psychedelic therapeutics in addressing mental health conditions.
Tonix Pharmaceuticals Launches Phase 2 Trial for Acute Stress Reaction Treatment
Tonix Pharmaceuticals has initiated a Department of Defense-backed clinical trial to evaluate TNX-102 SL as a potential treatment for acute stress reaction in motor vehicle trauma survivors, addressing a critical need in mental health care.
Creative Biolabs Advances Antibody Engineering with Innovative Glycosylation Technology
Creative Biolabs has developed a sophisticated analytical platform for monoclonal antibody glycan profiling, enhancing therapeutic antibody effectiveness through precise Fc region modifications. These technological improvements could significantly impact biopharmaceutical drug development.
D-Wave and Japan Tobacco Advance Drug Discovery Through Quantum AI
D-Wave Quantum Inc. and Japan Tobacco have successfully completed a quantum computing proof-of-concept project that demonstrates the potential of quantum artificial intelligence in pharmaceutical research, showing improved molecular design capabilities compared to classical methods.